Eric Venker Sells 218,041 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 218,041 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.42, for a total value of $2,271,987.22. Following the transaction, the chief operating officer now owns 896,869 shares of the company’s stock, valued at approximately $9,345,374.98. This trade represents a 19.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Eric Venker also recently made the following trade(s):

• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.28, for a total value of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The stock was sold at an average price of $11.54, for a total value of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The shares were sold at an average price of $11.82, for a total value of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.49, for a total value of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.32, for a total value of $1,132,000.00.

Roivant Sciences Price Performance

Shares of NASDAQ:ROIV opened at $10.56 on Friday. The business’s fifty day moving average price is $11.34 and its two-hundred day moving average price is $11.59. Roivant Sciences Ltd. has a fifty-two week low of $9.76 and a fifty-two week high of $13.06. The stock has a market capitalization of $7.69 billion, a price-to-earnings ratio of 1.87 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.65% and a net margin of 3,827.42%. Research analysts expect that Roivant Sciences Ltd. will post -1.19 EPS for the current fiscal year.

Institutional Trading of Roivant Sciences

Large investors have recently made changes to their positions in the business. Nordea Investment Management AB grew its holdings in shares of Roivant Sciences by 22.5% during the fourth quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock worth $3,306,000 after purchasing an additional 52,031 shares during the last quarter. TOMS Capital Investment Management LP bought a new stake in shares of Roivant Sciences during the third quarter worth $46,333,000. Barclays PLC grew its holdings in shares of Roivant Sciences by 19.7% during the third quarter. Barclays PLC now owns 459,521 shares of the company’s stock worth $5,302,000 after purchasing an additional 75,609 shares during the last quarter. Loomis Sayles & Co. L P lifted its stake in shares of Roivant Sciences by 13.3% during the third quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company’s stock valued at $45,147,000 after acquiring an additional 458,601 shares during the period. Finally, Retirement Systems of Alabama lifted its stake in shares of Roivant Sciences by 26.9% during the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock valued at $6,116,000 after acquiring an additional 112,286 shares during the period. Institutional investors own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a research report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Roivant Sciences has a consensus rating of “Buy” and a consensus price target of $18.08.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.